OTL-200 Granted Accelerated Assessment for Treatment of Metachromatic Leukodystrophy (MLD)
source: pixabay.com

OTL-200 Granted Accelerated Assessment for Treatment of Metachromatic Leukodystrophy (MLD)

  The development of treatments and medicines for diseases can take a long time. These treatments come from many hours of research, studies, trials, and waiting for approval from the…

Continue Reading OTL-200 Granted Accelerated Assessment for Treatment of Metachromatic Leukodystrophy (MLD)
Juvenile Male Patients with von Willebrand Disease More Likely to Experience Complications Than Female Counterparts
source: pixabay.com

Juvenile Male Patients with von Willebrand Disease More Likely to Experience Complications Than Female Counterparts

  The most common inherited bleeding disorder, von Willebrand disease, appears more likely to cause problems for juvenile males living with the disease than juvenile females, according to a study…

Continue Reading Juvenile Male Patients with von Willebrand Disease More Likely to Experience Complications Than Female Counterparts
Kate Middleton Visits Boys with Hunter Syndrome and Dystonic Cerebral Palsy
source: pixabay.com

Kate Middleton Visits Boys with Hunter Syndrome and Dystonic Cerebral Palsy

  East Anglia's Children's Hospices in Norfolk, U.K., has recently opened up its new facilities after renovations. To celebrate this opening, Kate Middleton, the Duchess of Cambridge, visited and spoke…

Continue Reading Kate Middleton Visits Boys with Hunter Syndrome and Dystonic Cerebral Palsy
This Business Owner and Baker’s Daughters Will Both Benefit from Newly Covered Cystic Fibrosis Drugs
source: pixabay.com

This Business Owner and Baker’s Daughters Will Both Benefit from Newly Covered Cystic Fibrosis Drugs

According to a story from dailypost.co.uk, Richard Mason, the millionaire founder of moneysupermarket.com, and and baker Alison Faire's daughters Annabelle (aged 4 years) and Imogen (aged 7 years) don't have…

Continue Reading This Business Owner and Baker’s Daughters Will Both Benefit from Newly Covered Cystic Fibrosis Drugs
A Recent Study from Yale Tracks the Progression of Scarring in Idiopathic Pulmonary Fibrosis
source: pixabay.com

A Recent Study from Yale Tracks the Progression of Scarring in Idiopathic Pulmonary Fibrosis

According to a story from EurekAlert!, a collaborative study headed by researchers from Yale University has furthered the understanding of the mechanisms and progression of fibrosis (scarring) in patients with…

Continue Reading A Recent Study from Yale Tracks the Progression of Scarring in Idiopathic Pulmonary Fibrosis
These Two Companies Just Announced a Partnership to Develop Multiple Gene Therapies
EliasSch / Pixabay

These Two Companies Just Announced a Partnership to Develop Multiple Gene Therapies

According to a story from BioSpace, the gene therapy companies Sarepta Therapeutics, Inc. and StrideBio, Inc. have recently announced the completion of a licensing and collaboration agreement that could lead…

Continue Reading These Two Companies Just Announced a Partnership to Develop Multiple Gene Therapies
ICYMI: hATTR Amyloidosis was Untreatable Until a Gene Silencing Drug was Approved in the UK
source: pixabay.com

ICYMI: hATTR Amyloidosis was Untreatable Until a Gene Silencing Drug was Approved in the UK

  An article appeared recently in BioNews announcing the first-ever approval of an RNA-based therapy for use on the British National Health Service. The name of the drug is Patisiran…

Continue Reading ICYMI: hATTR Amyloidosis was Untreatable Until a Gene Silencing Drug was Approved in the UK
This Treatment for Multiple Sclerosis Could be on its Way to Approval in the EU
source: pixabay.com

This Treatment for Multiple Sclerosis Could be on its Way to Approval in the EU

According to a story from finanznachricten.de, the drug company Novartis recently announced that the European Medicine Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive…

Continue Reading This Treatment for Multiple Sclerosis Could be on its Way to Approval in the EU